HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM)
Original Seminar Date November 2, 2023
6:00 pm ET - 7:30 pm ET


Program Overview

Hypertrophic cardiomyopathy (HCM) is estimated to affect some 700,000 Americans. Treatment usually includes the use of non-vasodilating beta-blockers followed by non-dihydropyridine calcium channel blockers if these therapies are not effective. Since the release of the most recent guidelines, mavacamten has been approved, and clinical trial data on emerging therapies including aficamten, ranolazine, and evolving gene therapies have been published. In our commitment to providing education that enhances clinical skills and improves patient outcomes, HFSA has identified a need for education in the selection and utilization of current and emerging therapies for HCM.

The HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM) is part of the educational seminar series, featuring a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.

1. Review the genetics, pathophysiology, and diagnosis of hypertrophic cardiomyopathy.
2. Discuss the clinical trial data and optimal use of current and emerging treatment options for the management of patients with hypertrophic cardiomyopathy.
3. Identify advanced treatment options for the management of challenging patients with hypertrophic cardiomyopathy.

• Carolyn Y. Ho, MD

• Carolyn Y. Ho, MD
• Sharelene Day, MD
• Victoria Parikh, MD
• Lynne Warner Stevenson, MD
• Michael Ayers, MD

• Welcome Remarks - Carolyn Y. Ho, MD
• Remembering the Basics: Diagnosis, Pathophysiology, and Genetics (Including the Family) -- Sharlene Day, MD
• Management: The Usual Approach, Carolyn Y. Ho, MD
• New Kids on the Block: New Medications and Future Approaches -- Victoria Parikh, MD
• Q&A -- All Faculty
• What Happens When the Usual is Not Enough: Referral and Advanced Therapy, Lynne Warner Stevenson, MD
• Case Presentation: Mild LV Systolic Dysfunction, Michael Ayers, MD
• What Happens When the Usual is Not Enough -- Lynne Warner Stevenson, MD, FHFSA
• Moderated Discusson -- All faculty
• Closing Remarks

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

• Carolyn Y. Ho, MD: Viz.ai (Biomedical startup) - Advisory Panel
• Sharlene Day, MD: Bristol-Myers Squibb (Pharmaceutical co.) - Research Support; Tenaya Therapeutics (Pharmaceutical co.) - Advisory Panel; Pfizer (Pharmaceutical co.) - Consultant; Cytokinetics (Pharmaceutical co.) - Data Monitoring Board; Biomarin (Pharmaceutical co.) - Consultant; Lexicon Pharmaceutical (pharmaceutical co.) - Consultant; Lexicon Pharmaceuticals (pharmaceutical co.) - Research Support.
• Victoria Parikh, MD: No Disclosures
• Lynne Warner Stevenson: No Disclosures
• Michael Ayers, MD:  Bristol-Myers Squibb - Advisory Panel

 
Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

In support of improving patient care, the Heart Failure Society of American is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, includes participation in the post-course evaluation.

• Hypertrophic cardiomyopathy
• HCM
• non-vasodilating beta-blockers
• non-dihydropyridine calcium channel blockers
• mavacamten
• aficamten
• ranolazine